Therapy for ALS

Amyotrophic lateral sclerosis (ALS) is a catastrophic degeneration of the nervous system with great need for disease-modifying treatments. Stefan Pulst, MD, and his collaborator Daniel Scoles, PhD, were studying a lesser-known but similarly dire condition (spinocerebellar ataxia 2, SCA2) when they identified a gene relevant to both diseases. Continue reading → Therapy for ALS

Research Statement

Daniel R. Scoles, PhD is Associate Professor of Neurology. His scientific training includes biochemistry, genetics of natural populations, and neurology with emphasis on brain tumor research. Dr. Scoles’s research objectives are centered on the identification of drugs for the treatment of spinocerebellar ataxia type 2 (SCA2) and Parkinson’s disease. Drug discovery methodologies used by Dr. Scoles include quantitative high throughput screening (qHTS) and antisense oligonucleotide screening. His research is promoted by collaborative partnerships with industry and the National Institutes of Health (NCATS). Dr. Scoles also investigates molecular mechanisms of disease gene expression control aimed at identifying new therapeutic targets and understanding drug action. Dr. Scoles is currently supported by grants from the NINDS and the Harrington Discovery Institute.